2025
Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation
Baro M, Lee H, Kelley V, Lou R, Phoomak C, Politi K, Zeiss C, Van Zandt M, Contessa J. Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. Cell Chemical Biology 2025, 32: 839-853.e6. PMID: 40494352, DOI: 10.1016/j.chembiol.2025.05.005.Peer-Reviewed Original ResearchConceptsN-glycosylationTrafficking of cell surface receptorsInhibits N-glycosylationCell surface receptorsGlycan synthesisCatalytic subunitOligosaccharyltransferaseEnzymatic activitySurface receptorsSTT3BSTT3ACharacterized in vitroDownstream effectsLung cancer xenograftsTherapeutic targetPatient-derivedBiological activityTumor regressionCancer xenograftsSmall moleculesGrowth delayTherapeutic agentsGlycansBroxyquinoline targets NLRP3 to inhibit inflammasome activation and alleviate NLRP3-associated inflammatory diseases
Tang H, Zou X, Chen P, Wang Y, Gao S, Wang T, Xu Y, Ji S. Broxyquinoline targets NLRP3 to inhibit inflammasome activation and alleviate NLRP3-associated inflammatory diseases. International Immunopharmacology 2025, 156: 114687. PMID: 40253767, DOI: 10.1016/j.intimp.2025.114687.Peer-Reviewed Original ResearchConceptsExperimental autoimmune encephalomyelitisNLR family pyrin domain-containing 3Inflammasome activationInflammatory diseasesASC speck formationInflammasome-associated diseasesNEK7-NLRP3 interactionDamage signalingNF-kB pathwayHost defensePyrin domain-containing 3Speck formationAIM2 inflammasome activationActivation of NLRP3 inflammasomeFamily pyrin domain-containing 3Autoimmune encephalomyelitisMurine modelInterleukin-1bIL-1BInhibiting inflammasome activationNLRP3 inflammasome inhibitorAntimicrobial drugsNF-kBProteinTherapeutic agentsA Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021
Jacobs J, Adkins B, Booth G, Stanek C, Allen E, Grossman B, Stephens L, Crowe E, Daou L, Marques M, Siniard R, Wallace L, Yamada C, Duque M, Wu Y, Aljuboori O, Harrington T, Byrnes D, Eichbaum Q, Villalba C, Juskewitch J, Klapper E, Perez‐Alvarez I, Klein M, Aldarweesh F, Alkhateb R, Parsons M, Schlueter A, Tormey C, Wheeler A, Powers A, Webb C, Yates S, Bloch E, Raval J. A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021. Journal Of Clinical Apheresis 2025, 40: e70017. PMID: 40145682, PMCID: PMC11948952, DOI: 10.1002/jca.70017.Peer-Reviewed Original ResearchConceptsImmune thrombotic thrombocytopenic purpuraTherapeutic plasma exchangeThrombotic thrombocytopenic purpuraThrombocytopenic purpuraStandardization of treatment regimensMicroangiopathic hemolytic anemiaThirty-day mortalityPlasma exchangeADAMTS13 deficiencyThirty-dayMulticenter studyTreatment regimensHemolytic anemiaMicrovascular occlusionInitial episodesReplacement fluidCaplacizumabTherapeutic agentsPatientsDisease episodesPurpuraMortalityTherapyEpisodesTreatment practicesNCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
Greenberg P, Stone R, Abaza Y, Al-Kali A, Anand S, Ball B, Bennett J, Borate U, Brunner A, Chai-Ho W, Curtin P, DeZern A, Gaensler K, Gahvari Z, Garcia-Manero G, Griffiths E, Haque T, Jacoby M, Jonas B, Keel S, Khanal R, Kishtagari A, Madanat Y, Maness L, McCurdy S, McMahon C, Odenike O, Osman A, Reddy V, Sallman D, Sayar H, Shallis R, Singh A, Tanaka T, Thota S, Kovach E, Nguyen J, Hochstetler C. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025. Journal Of The National Comprehensive Cancer Network 2025, 23: 66-75. PMID: 40073835, DOI: 10.6004/jnccn.2025.0013.Peer-Reviewed Original ResearchConceptsNCCN Guidelines InsightsHigher-risk MDSComprehensive care of patientsPrognostic significanceNCCN guidelinesClinical evidenceCare of patientsTreatment recommendationsMultidisciplinary panelNovel therapeuticsTherapeutic agentsNCCNLowered riskComprehensive careTreatmentBiological factorsPatientsCRISPR-Cas9 system in autosomal dominant polycystic kidney disease: a comprehensive review
Kang S, Park S, Lee M, Kronbichler A, Shin J. CRISPR-Cas9 system in autosomal dominant polycystic kidney disease: a comprehensive review. Childhood Kidney Diseases 2025, 29: 4-11. DOI: 10.3339/ckd.25.008.Peer-Reviewed Original ResearchGenetic kidney diseaseCRISPR/CRISPR-associated protein 9Genetic diseasesAutosomal dominant polycystic kidney diseaseDominant polycystic kidney diseaseFunction of genesPolycystic kidney diseaseCRISPR-Cas9 SystemCRISPR-Cas9 technologyGenomic sitesPathogenic genesDevelopment of therapeutic agentsCRISPR-Cas9CRISPR technologyGenesProtein 9Kidney developmentGene editingGene mutationsKidney diseaseMutationsTherapeutic agentsCRISPREffects of drugsβ-Ionone facilitates ex vivo airway smooth muscle relaxation via extraocular opsin-3 light receptor activation
Uribe S, Shany E, Zhang Y, Wu A, Dan W, Perez-Zoghbi J, Emala C, Yim P. β-Ionone facilitates ex vivo airway smooth muscle relaxation via extraocular opsin-3 light receptor activation. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2025, 328: l526-l537. PMID: 39937635, DOI: 10.1152/ajplung.00227.2024.Peer-Reviewed Original ResearchConceptsAirway smooth muscle relaxationOpsin 3Severity of asthma exacerbationsAirway smooth muscle cellsDose-dependent relaxationTherapeutic agentsAirways in vitroPrecision-cut lung slicesSmooth muscle relaxationSmooth muscle cellsAttenuated relaxationWire myographyDietary intakeDecreased relaxationAirway pathologyIncreased riskReceptor activationAsthma exacerbationsMuscle cellsLower airwaysLung slicesMRNA expressionMuscle relaxationTracheal ringsAirway
2024
Nanotechnology approaches to drug delivery for the treatment of ischemic stroke
Peng B, Mohammed F, Tang X, Liu J, Sheth K, Zhou J. Nanotechnology approaches to drug delivery for the treatment of ischemic stroke. Bioactive Materials 2024, 43: 145-161. PMID: 39386225, PMCID: PMC11462157, DOI: 10.1016/j.bioactmat.2024.09.016.Peer-Reviewed Original ResearchBlood-brain barrierClinical translationClinical trialsFDA-approved pharmacotherapiesReview therapeutic agentsIschemic strokeTherapeutic agentsEffective treatment optionDrug deliveryTreatment of ischemic strokePotential clinical translationGlobal public health concernImprove delivery efficiencyTreatment optionsTreatment strategiesIschemic brainPublic health concernStroke pharmacotherapyEngineered nanoparticlesStroke treatment strategiesDelivery efficiencyNanotechnological approachesDrugPharmacotherapyStrokeGlobal pandemic preparedness: learning from the COVID-19 vaccine development and distribution
Agampodi S, Mogeni O, Chandler R, Pansuriya M, Kim J, Excler J. Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution. Expert Review Of Vaccines 2024, 23: 761-772. PMID: 39167221, DOI: 10.1080/14760584.2024.2395546.Peer-Reviewed Original ResearchConceptsPandemic vaccine developmentVaccine developmentGlobal health securityField of vaccinologyVaccine deliveryFuture pandemicsTherapeutic agentsVaccineHealth securityCOVID-19 vaccine developmentResponse frameworkPandemic preparednessDistribution of vaccinesStakeholder websitesCOVID-19Adequate fundingVaccine innovationCOVID-19 pandemicPotential Role for Buprenorphine in the Management of Comorbid Depression Among People with Chronic Pain and Long-Term Opioid Therapy Dependence
Manhapra A, Rosenheck R, Becker W. Potential Role for Buprenorphine in the Management of Comorbid Depression Among People with Chronic Pain and Long-Term Opioid Therapy Dependence. 2024, 148-164. DOI: 10.1093/9780197675250.003.0009.Peer-Reviewed Original ResearchLong-term opioid therapyKappa-opioid receptorsChronic painOpioid receptorsKappa-opioid receptor antagonismManagement of comorbid depressionTherapeutic agentsMOR agonismOpioid therapyOpioid taperAntidepressant effectsWorsening painOpioid dependenceSafety profileAgonist actionPoor outcomeClinical trialsAssociated with worsening depressionPainEtiological driversBuprenorphineReceptor affinityComorbid depressionOpioidReceptorsLipid mediators in neutrophil biology: inflammation, resolution and beyond
Ghodsi A, Hidalgo A, Libreros S. Lipid mediators in neutrophil biology: inflammation, resolution and beyond. Current Opinion In Hematology 2024, 31: 175-192. PMID: 38727155, PMCID: PMC11301784, DOI: 10.1097/moh.0000000000000822.Peer-Reviewed Original ResearchConceptsG protein-coupled receptorsAcute inflammationLipid mediatorsResolution of acute inflammationChronic inflammatory disordersExcessive neutrophil infiltrationCell surface G protein-coupled receptorsEndogenous lipid mediatorsTissue repair mechanismsResolution of inflammationPro-resolving mediatorsNeutrophil infiltrationChronic inflammationIschemic eventsInflammatory disordersInflammatory insultInflammation sitesInflammationNeutrophil phagocytosisCardiovascular diseaseNeutrophil functionNeutrophilsTherapeutic agentsNeutrophil heterogeneityNeutrophil apoptosis
2023
Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders
Rhee T, Davoudian P, Sanacora G, Wilkinson S. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. Drug Discovery Today 2023, 28: 103818. PMID: 37925136, DOI: 10.1016/j.drudis.2023.103818.Peer-Reviewed Original ResearchPsychiatric disordersLysergic acid diethylamideClinical trialsUS Clinical Trials RegistryClinical Trials RegistryPotential therapeutic effectsTrials RegistryTherapeutic effectPotential therapyTherapeutic agentsN-dimethyltryptamineAcid diethylamideLargest causePsychedelic compoundsDisordersPsychotherapeutic approachesSafety concernsTrialsPotential interactive effectsCutting-edge reviewPsychedelic substancesRegistryTherapyNew Therapies in Melanoma: Current Trends, Evolving Paradigms, and Future Perspectives.
Shafi S, Challa B, Parwani A, Aung T. New Therapies in Melanoma: Current Trends, Evolving Paradigms, and Future Perspectives. Cutis 2023, 112: e32-e39. PMID: 38091429, DOI: 10.12788/cutis.0911.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLymphocyte-activating gene-3Early phase clinical trialsPrimary treatment failureAggressive skin cancerNew therapeutic agentsICI therapyCheckpoint inhibitorsNovel immunotherapiesMelanoma patientsTreatment failureMetastatic melanomaPredictive biomarkersLong-term benefitsClinical trialsClinical careNew therapiesTherapeutic strategiesAlternative treatmentSkin cancerTherapy outcomeTherapeutic agentsNovel targetNovel therapeuticsPatientsThe Potential of Psychedelics for the Treatment of Episodic Migraine
Schindler E. The Potential of Psychedelics for the Treatment of Episodic Migraine. Current Pain And Headache Reports 2023, 27: 489-495. PMID: 37540398, DOI: 10.1007/s11916-023-01145-y.Peer-Reviewed Original ResearchConceptsEpisodic migrainePotential of psychedelicsWeekly migraine daysPsychedelic drugsMigraine daysPain intensityTransitional treatmentCluster headacheHeadache disordersPreventive effectClinical trialsSingle administrationTherapeutic effectAbortive effectMigrainePsychiatric conditionsReviewThis reviewTherapeutic agentsDrugsAdditional findingsMedicinal usePsychedelicsTreatmentPotential medicinal usePsilocybinCase report: Psychedelic-induced seizures captured by intracranial electrocorticography
Blond B, Schindler E. Case report: Psychedelic-induced seizures captured by intracranial electrocorticography. Frontiers In Neurology 2023, 14: 1214969. PMID: 37456653, PMCID: PMC10343433, DOI: 10.3389/fneur.2023.1214969.Peer-Reviewed Original ResearchDrug classesRight temporal lobe epilepsyDrug-induced seizuresRisk of seizuresTemporal lobe epilepsyHistory of epilepsyResponsive neurostimulation systemUnique clinical benefitsSeizure frequencyClinical benefitLobe epilepsyLarge doseDrug dosesDrug useSeizuresClassic psychedelicsIntracranial electrocorticographyNeurostimulation systemTherapeutic agentsAdverse effectsPsychedelic compoundsPsychedelic drug useClinical applicationEpilepsyRiskMitochondria-targeted cyclometalated iridium-β-carboline complexes as potent non-small cell lung cancer therapeutic agents
Chen J, Guo X, Li D, Tang H, Gao J, Yu W, Zhu X, Sun Z, Huang Z, Chen L. Mitochondria-targeted cyclometalated iridium-β-carboline complexes as potent non-small cell lung cancer therapeutic agents. Metallomics 2023, 15: mfad035. PMID: 37204038, DOI: 10.1093/mtomcs/mfad035.Peer-Reviewed Original ResearchConceptsLoss of mitochondrial membrane potentialIridium complexesDeath of A549 cellsMitochondrial membrane potentialA549 cellsDepletion of cellular ATPElevation of reactive oxygen speciesNSCLC therapeutic agentsMitochondrial eventsCaspase pathwayCancer therapeutic agentsReactive oxygen speciesPotential antitumor effectsCellular ATPDevelopment of antitumor drugsMulticellular tumor spheroid modelAntitumor effectNon-smallTumor spheroid modelTumor growthMembrane potentialIridiumOxygen speciesTherapeutic agentsAntitumor drugsWhat’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
Awada H, Gurnari C, Xie Z, Bewersdorf J, Zeidan A. What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers 2023, 15: 2248. PMID: 37190176, PMCID: PMC10137017, DOI: 10.3390/cancers15082248.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute myeloid leukemiaMDS/AML patientsEarly clinical trialsPotential therapeutic agentAML patientsMultidrug combinationsClinical trialsMyeloid leukemiaMyeloid neoplasmsRational approachSingle agentCurrent managementTherapeutic potentialStandardized guidelinesTherapeutic agentsMutational characteristicsPatientsNeoplasmsLatest findingsGenomic factorsCellular adaptationAgentsHMA resistanceFailureLeukemiaCell-free fetal DNA impairs trophoblast migration in a TLR9-dependent manner and can be reversed by hydroxychloroquine
León-Martínez D, Lynn T, Abrahams V. Cell-free fetal DNA impairs trophoblast migration in a TLR9-dependent manner and can be reversed by hydroxychloroquine. Journal Of Reproductive Immunology 2023, 157: 103945. PMID: 37062109, DOI: 10.1016/j.jri.2023.103945.Peer-Reviewed Original ResearchConceptsToll-like receptor 9Aspirin-triggered lipoxinsODN 2216Pathogenesis of preeclampsiaTLR9-dependent mannerNovel therapeutic approachesTrophoblast cell modelReceptor 9CpG oligodeoxynucleotideTLR9 inhibitorPlacental functionTherapeutic approachesCell-free fetal DNACpG motifsTherapeutic agentsHCQPreeclampsiaHydroxychloroquineFetal DNACell viabilityCffDNAMolecular underpinningsCell modelInhibitionASA
2022
Non-Modulator Therapies Developing a Therapy for Every Cystic Fibrosis Patient
Egan M. Non-Modulator Therapies Developing a Therapy for Every Cystic Fibrosis Patient. Clinics In Chest Medicine 2022, 43: 717-725. PMID: 36344076, DOI: 10.1016/j.ccm.2022.06.011.Peer-Reviewed Original ResearchConceptsModulator therapyCystic fibrosisCystic fibrosis transmembrane conductance regulator (CFTR) modulator therapiesCFTR modulator therapyTreatment of CFCystic fibrosis patientsGenetic-based therapiesMost patientsCF patientsFibrosis patientsTherapyPremature termination codon mutationsTherapeutic agentsPatientsDNA therapyRNA therapyTermination codon mutationsCodon mutationAn update on the diagnosis and treatment of adrenoleukodystrophy
Gujral J, Sethuram S. An update on the diagnosis and treatment of adrenoleukodystrophy. Current Opinion In Endocrinology Diabetes And Obesity 2022, 30: 44-51. PMID: 36373727, DOI: 10.1097/med.0000000000000782.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantTreatment optionsOnly successful treatment optionManagement of patientsStem cell transplantRecommended Uniform Screening PanelSuccessful treatment optionPotential treatment optionUniform Screening PanelTreatment of adrenoleukodystrophyAdrenal insufficiencyCell transplantCerebral adrenoleukodystrophyConsensus guidelinesNeurological changesNovel therapiesEarly diagnosisAnimal modelsAmerican AcademyAdrenoleukodystrophyTherapeutic agentsScreening panelDiagnosisTherapyDiseaseUterine administration of C-X-C motif chemokine ligand 12 increases the pregnancy rates in mice with induced endometriosis
Rosa-E-Silva ACJS, Mamillapalli R, Rosa-E-Silva JC, Ucar A, Schwartz J, Taylor HS. Uterine administration of C-X-C motif chemokine ligand 12 increases the pregnancy rates in mice with induced endometriosis. F&S Science 2022, 4: 65-73. PMID: 36252793, DOI: 10.1016/j.xfss.2022.10.003.Peer-Reviewed Original ResearchConceptsC motif chemokine ligand 12Endometriosis groupPregnancy rateChemokine ligand 12Alpha v beta 3 integrinUterine injectionBeta 3 integrinBMDC recruitmentProgesterone receptorMouse modelBone marrow-derived cell recruitmentHigher cumulative pregnancy rateLigand 12Therapeutic agentsEndometrial receptivity defectsCumulative pregnancy rateEndometrial receptivity markersSham surgery groupBone marrow transplantationLower pregnancy ratesAcademic medical centerPotential therapeutic agentReceptivity markersSurgery groupInduced endometriosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply